Skip to main content

Pharma's presidential picks

In an industry known for backing Republicans, Sen. Barack Obama has emerged as a surprising pharma favorite in the US presidential election. In April, Obama won a mock election at the annual DTC national meeting, a drug advertising conference, with a 53% to 46% victory over Sen. John McCain. Drug companies have also put the money where their mouth is: Pharma has donated three times more to the Obama campaign than to McCain's. According to a linkurl:Bloomberg News report;https://www.bloomber

Written byMegan Scudellari
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
In an industry known for backing Republicans, Sen. Barack Obama has emerged as a surprising pharma favorite in the US presidential election. In April, Obama won a mock election at the annual DTC national meeting, a drug advertising conference, with a 53% to 46% victory over Sen. John McCain. Drug companies have also put the money where their mouth is: Pharma has donated three times more to the Obama campaign than to McCain's. According to a linkurl:Bloomberg News report;https://www.bloomberg.com/apps/news?pid=newsarchive&sid=aRCVqfSQ43Eo citing data from the Center for Responsive Politics (CRP), pharma execs and employees have donated $450,094 to Obama, compared to $132,575 to McCain. CRP's Web site also lists linkurl:figures;https://www.opensecrets.org/industries/recips.php?cycle=2008&ind=H04 for donations that include pharmaceutical companies and makers of medical devices and other health-related products: Obama is ranked as the top recipient of donations in that category with $848,001, while McCain is in fourth place (behind Clinton and Romney) with $347,375. It's a clear contrast to the 2004 election, in which drug industry donations to George W. Bush almost doubled those to John Kerry. This year's top pharma donations come from Pfizer, Amgen, and Johnson & Johnson, according to CRP's website. Republican lobbyist John Feehery told Bloomberg the lack of industry funding helps McCain, solidifying his reputation as someone who fights special interests. "He goes after these companies and they don't like it." In a linkurl:recent CNBC article,;https://www.cnbc.com/id/26220788 analysts at Stratega Research Partners forecast that both Obama and McCain would be bad for big pharma because of their support for government regulation of Medicare drugs and reimportation, buy-back of American made drugs at abroad prices. Both candidates are expected to be positive forces for generics as the two men endorse moving drugs to the market faster, the article notes. For more on science in the upcoming election, stay tuned for our September issue and accompanying online content, for a look at key thought leaders poised to influence science policy during the next administration, and featuring a round-up of how the candidates stack up on science-related issues. August 19: This blog has been updated from a previous version
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
From Pilot to Practice: Advancing Regulatory Reliance

From Pilot to Precedent: A Year of Regulatory Innovation through PRISM and What it Means for Cloud Adoption in Regulatory Submissions

DNAnexus
Thumbnail

Make It Local, Make It Last: The Evolution of mRNA Protein Replacement Therapy

Improving Western Blot Analysis of Biofluid Samples

Improving Western Blot Analysis of Biofluid Samples

Bio-Rad
Reducing AAV Sample Consumption With Multiwavelength SV-AUC

Reducing AAV Sample Consumption With Multiwavelength SV-AUC

​Beckman Coulter

Products

Sino Biological Logo

Sino Biological Advances AI-Designed Molecule Validation with 4RISE™

Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler
3D multicolored conceptual image of antibody molecules

Premium BsAb: LC-MS-Assisted Bispecific Antibody Production with >98% Heterodimer Purity

WuXi Biologics
Abstract conceptual image of AI technology for medical science research.

Exploring a New Era of Pharmaceutical Innovation